Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-κB pathway activation.

European journal of haematology - 1 Sept 2020

Dash Ajeeta B, Zhang Jacob, Shen Lei, Li Bin, Berg Deborah, Lin Jianchang, Avet-Loiseau Hervé, Bahlis Nizar J, Moreau Philippe, Richardson Paul G, Di Bacco Alessandra

Abstract excerpt

OBJECTIVES: Evaluating potential relationships between progression-free survival (PFS) and tumor gene expression patterns and mutational status was an exploratory objective of the phase 3 TOURMALINE-MM1 study (NCT01564537) of ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in 722 patients with relapsed/refractory multiple myeloma (MM). METHODS: We utilized gene expression and mutation data from screening...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Boron Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dexamethasone

Share to Glycine

Share to Lenalidomide

Share to Multiple Myeloma

Share to NF-kappa B

Share to Progression-Free Survival

Source

Open in PubMed Open full text

Identifiers

PMID: 32350909
DOI: 10.1111/ejh.13435
PMCID: PMC7497066

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical benefit of ixazomib plus lenalidomide-dexamethasone in myeloma patients with non-canonical NF-κB pathway activation.PMID 32350909Read ↗

Inflammatory microenvironment impairs the therapeutic effect of daratumumab-lenalidomide in multiple myelomaSemantic proximity Read ↗

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myelomaSemantic proximity Read ↗

Targeting NF-κB Signaling for Multiple MyelomaSemantic proximity Read ↗

MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug ResistanceSemantic proximity Read ↗

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myelomaSemantic proximity Read ↗

Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysisSemantic proximity Read ↗

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.Semantic proximity Read ↗

ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone.Semantic proximity Read ↗

Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogeneticsSemantic proximity Read ↗

IMiD Resistance in Multiple Myeloma: Current Understanding of the Underpinning Biology and Clinical ImpactSemantic proximity Read ↗

Effect of MAPK activation via mutations in NRAS, KRAS and BRAF on clinical outcome in newly diagnosed multiple myeloma.Semantic proximity Read ↗

Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkBSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.